ADMA Reports Q1 Revenue of $114.49M, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Reports Q1 revenue $114.49M, consensus $139.97M. "During the first quarter, the market for U.S. plasma derived therapies and immunoglobulin experienced increased competitive dynamics which, along with variability in distributor ordering patterns, created near-term topline pressures, particularly impacting BIVIGAM," said Adam Grossman, President and Chief Executive Officer of ADMA. "Importantly, these dynamics were limited to distribution and inventory behavior and we believe do not reflect any deterioration in underlying ASCENIV demand, where fundamentals remained strong and continue to improve - with record utilization growth throughout the quarter, as illustrated by ASCENIV's 28% year-over-year revenue growth. We continue to see strength across key ASCENIV demand metrics, including record new patient starts, growing prescriber breadth, product pull-through and patient adherence, and we are encouraged that the second quarter run rate based on April demand is in-line with the level of first quarter direct sales."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into ADMA Biologics for Securities Violations
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, particularly questioning the authenticity of its reported 20% revenue growth in 2025, suggesting possible channel stuffing to mask declining demand.
- Revenue Growth Concerns: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which artificially inflated revenue; without this scheme, the company would have faced a 3% revenue decline in 2025 instead of the reported growth.
- Stock Price Plunge: The news of the investigation caused ADMA Biologics' stock price to drop by 29% over two trading days, falling from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating severe market concerns regarding the company's financial health.
- Legal Options for Investors: Investors are encouraged to submit their information for legal support, with BFA offering representation on a contingency fee basis, highlighting a commitment to protecting investor rights, which may also impact ADMA's future financing capabilities and market trust.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Investigation Announcement: Bleichmar Fonti & Auld LLP has launched an investigation into ADMA Biologics for potential violations of federal securities laws, particularly concerning the legitimacy of its reported 20% revenue growth in 2025.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA induced a distributor to stockpile ASCENIV, artificially inflating revenue; without this scheme, the company would have faced a 3% revenue decline instead of the reported 20% growth.
- Stock Price Plunge: The news of the investigation led to a 29% drop in ADMA's stock price over two trading days, falling from $13.59 per share on March 23 to $9.63 on March 25, indicating significant market concerns regarding the company's financial health.
- Legal Options for Investors: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency fee basis, highlighting their commitment to protecting shareholder rights.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ADMA Biologics has engaged in securities fraud or other unlawful business practices, prompting investors to reach out for more information, indicating serious concerns regarding corporate governance.
- Short Report Allegations: On March 24, 2026, Culper Research published a short report alleging that ADMA's reported growth is fictitious, driven by channel stuffing and undisclosed related party distributors, estimating a 3% revenue decline in 2025 without channel stuffing, which significantly undermines investor confidence.
- Stock Price Plunge: Following the short report's release, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share on March 24, 2026, reflecting strong market skepticism about the company's financial transparency.
- Withdrawal of Long-term Guidance: On May 6, 2026, ADMA withdrew its long-term financial guidance due to evolving competitive dynamics in the U.S. plasma products and immunoglobulin market, leading to a further stock price drop of $1.61, or 15.97%, to close at $8.47 per share on May 7, indicating increasing market pressures on the company.
See More
ADMA Biologics Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against ADMA Biologics for possibly issuing misleading business information, indicating a strong commitment to protecting investor rights with no out-of-pocket costs.
- Stock Price Impact: On March 24, 2026, ADMA Biologics shares plummeted by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue, reflecting market concerns over the company's financial transparency.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against ADMA to recover investor losses, demonstrating the firm's dedication to advocating for investor rights in the face of alleged corporate misconduct.
- Law Firm Reputation: Rosen Law Firm has recovered over $438 million for investors in 2019 alone and is recognized for its expertise in securities class actions, highlighting its strong track record and credibility in handling similar cases.
See More
Zacks Adds Three Stocks to Strong Sell List
- Amerant Bancorp Downgrade: Amerant Bancorp (AMTB) has seen its Zacks consensus estimate for current year earnings revised down by nearly 13.7% over the past 60 days, indicating a significant loss of market confidence that could lead to stock sell-offs and negatively impact its price performance.
- ADMA Biologics Earnings Drop: ADMA Biologics (ADMA) has experienced a downward revision of approximately 12.5% in its current year earnings estimate by Zacks over the last 60 days, reflecting increased competitive pressures in the biopharmaceutical market that may affect its future financing capabilities and market share.
- Adecco Earnings Decline: Adecco (AHEXY) has had its current year earnings consensus estimate revised down by 9% in the past 60 days, which could weaken its competitive position in the recruitment market and impact its ability to acquire and retain clients.
- Zacks Strong Sell List: These three stocks have been added to the Zacks Rank #5 (Strong Sell) list, indicating analysts' pessimistic outlook on their future performance, prompting investors to carefully assess the risks of holding these stocks.
See More
ADMA Biologics Under Investigation for Securities Fraud Allegations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, focusing on allegations that the reported 20% revenue growth in 2025 was a result of a channel stuffing scheme to obscure declining demand.
- Revenue Growth Scrutiny: A report by Culper Research revealed that ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allowed the company to report growth that was not genuine; without this scheme, the company would have faced a 3% revenue decline in 2025.
- Stock Price Plunge: Following the report, ADMA Biologics' stock price fell by 29% over two trading days, dropping from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating significant market concerns regarding the company's financial integrity.
- Legal Options for Investors: Investors are encouraged to submit their information for potential legal recourse, with BFA offering representation on a contingency fee basis, highlighting their commitment to protecting shareholder rights and potentially impacting future investor confidence.
See More
Investigation into ADMA Biologics for Securities Violations
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, particularly questioning the authenticity of its reported 20% revenue growth in 2025, suggesting possible channel stuffing to mask declining demand.
- Revenue Growth Concerns: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which artificially inflated revenue; without this scheme, the company would have faced a 3% revenue decline in 2025 instead of the reported growth.
- Stock Price Plunge: The news of the investigation caused ADMA Biologics' stock price to drop by 29% over two trading days, falling from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating severe market concerns regarding the company's financial health.
- Legal Options for Investors: Investors are encouraged to submit their information for legal support, with BFA offering representation on a contingency fee basis, highlighting a commitment to protecting investor rights, which may also impact ADMA's future financing capabilities and market trust.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Investigation Announcement: Bleichmar Fonti & Auld LLP has launched an investigation into ADMA Biologics for potential violations of federal securities laws, particularly concerning the legitimacy of its reported 20% revenue growth in 2025.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA induced a distributor to stockpile ASCENIV, artificially inflating revenue; without this scheme, the company would have faced a 3% revenue decline instead of the reported 20% growth.
- Stock Price Plunge: The news of the investigation led to a 29% drop in ADMA's stock price over two trading days, falling from $13.59 per share on March 23 to $9.63 on March 25, indicating significant market concerns regarding the company's financial health.
- Legal Options for Investors: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency fee basis, highlighting their commitment to protecting shareholder rights.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ADMA Biologics has engaged in securities fraud or other unlawful business practices, prompting investors to reach out for more information, indicating serious concerns regarding corporate governance.
- Short Report Allegations: On March 24, 2026, Culper Research published a short report alleging that ADMA's reported growth is fictitious, driven by channel stuffing and undisclosed related party distributors, estimating a 3% revenue decline in 2025 without channel stuffing, which significantly undermines investor confidence.
- Stock Price Plunge: Following the short report's release, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share on March 24, 2026, reflecting strong market skepticism about the company's financial transparency.
- Withdrawal of Long-term Guidance: On May 6, 2026, ADMA withdrew its long-term financial guidance due to evolving competitive dynamics in the U.S. plasma products and immunoglobulin market, leading to a further stock price drop of $1.61, or 15.97%, to close at $8.47 per share on May 7, indicating increasing market pressures on the company.
See More
ADMA Biologics Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against ADMA Biologics for possibly issuing misleading business information, indicating a strong commitment to protecting investor rights with no out-of-pocket costs.
- Stock Price Impact: On March 24, 2026, ADMA Biologics shares plummeted by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue, reflecting market concerns over the company's financial transparency.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against ADMA to recover investor losses, demonstrating the firm's dedication to advocating for investor rights in the face of alleged corporate misconduct.
- Law Firm Reputation: Rosen Law Firm has recovered over $438 million for investors in 2019 alone and is recognized for its expertise in securities class actions, highlighting its strong track record and credibility in handling similar cases.
See More
Zacks Adds Three Stocks to Strong Sell List
- Amerant Bancorp Downgrade: Amerant Bancorp (AMTB) has seen its Zacks consensus estimate for current year earnings revised down by nearly 13.7% over the past 60 days, indicating a significant loss of market confidence that could lead to stock sell-offs and negatively impact its price performance.
- ADMA Biologics Earnings Drop: ADMA Biologics (ADMA) has experienced a downward revision of approximately 12.5% in its current year earnings estimate by Zacks over the last 60 days, reflecting increased competitive pressures in the biopharmaceutical market that may affect its future financing capabilities and market share.
- Adecco Earnings Decline: Adecco (AHEXY) has had its current year earnings consensus estimate revised down by 9% in the past 60 days, which could weaken its competitive position in the recruitment market and impact its ability to acquire and retain clients.
- Zacks Strong Sell List: These three stocks have been added to the Zacks Rank #5 (Strong Sell) list, indicating analysts' pessimistic outlook on their future performance, prompting investors to carefully assess the risks of holding these stocks.
See More
ADMA Biologics Under Investigation for Securities Fraud Allegations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, focusing on allegations that the reported 20% revenue growth in 2025 was a result of a channel stuffing scheme to obscure declining demand.
- Revenue Growth Scrutiny: A report by Culper Research revealed that ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allowed the company to report growth that was not genuine; without this scheme, the company would have faced a 3% revenue decline in 2025.
- Stock Price Plunge: Following the report, ADMA Biologics' stock price fell by 29% over two trading days, dropping from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating significant market concerns regarding the company's financial integrity.
- Legal Options for Investors: Investors are encouraged to submit their information for potential legal recourse, with BFA offering representation on a contingency fee basis, highlighting their commitment to protecting shareholder rights and potentially impacting future investor confidence.
See More
